Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Mineralys Therapeutics Inc (MLYS)

Mineralys Therapeutics Inc (MLYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 985,466
  • Shares Outstanding, K 64,876
  • Annual Sales, $ 0 K
  • Annual Income, $ -177,810 K
  • EBIT $ -192 M
  • EBITDA $ -192 M
  • 60-Month Beta -0.30
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.91

Options Overview Details

View History
  • Implied Volatility 77.26% ( -1.65%)
  • Historical Volatility 68.66%
  • IV Percentile 28%
  • IV Rank 15.87%
  • IV High 403.07% on 02/28/25
  • IV Low 15.79% on 06/21/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 35
  • Volume Avg (30-Day) 362
  • Put/Call OI Ratio 1.35
  • Today's Open Interest 4,208
  • Open Int (30-Day) 4,894

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -1.06
  • Number of Estimates 2
  • High Estimate -0.88
  • Low Estimate -1.24
  • Prior Year -0.83
  • Growth Rate Est. (year over year) -27.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.77 +19.58%
on 04/21/25
15.94 -4.20%
on 05/09/25
+1.35 (+9.70%)
since 04/14/25
3-Month
8.24 +85.29%
on 02/25/25
18.38 -16.92%
on 03/19/25
+5.03 (+49.12%)
since 02/14/25
52-Week
8.24 +85.29%
on 02/25/25
18.38 -16.92%
on 03/19/25
+2.21 (+16.92%)
since 05/14/24

Most Recent Stories

More News
Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

MLYS : 15.40 (+1.38%)
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

MLYS : 15.40 (+1.38%)
Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

MLYS : 15.40 (+1.38%)
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)

MLYS : 15.40 (+1.38%)
Mineralys, Sana, Aeon: These 3 Biotech Stocks Saw The Sharpest Retail Interest Spike In Q1

Three small-cap stocks have intrigued Stocktwits users the most among the biotech sector this year, thanks to promising data from clinical trials and a leadership shuffle.

SANA : 1.7700 (-1.12%)
MLYS : 15.40 (+1.38%)
AEON : 0.4852 (-3.39%)
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)

MLYS : 15.40 (+1.38%)
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

MLYS : 15.40 (+1.38%)
Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

MLYS : 15.40 (+1.38%)
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Expo

MLYS : 15.40 (+1.38%)
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week

Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.

TNYA : 0.3801 (-3.63%)
CSCI : 3.45 (-1.43%)
MLYS : 15.40 (+1.38%)
SWTX : 46.24 (+0.04%)
MGX : 1.5011 (-6.18%)

Business Summary

Mineralys Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Mineralys Therapeutics Inc. is based in RADNOR, Pa.

See More

Key Turning Points

3rd Resistance Point 16.82
2nd Resistance Point 16.32
1st Resistance Point 15.75
Last Price 15.40
1st Support Level 14.68
2nd Support Level 14.18
3rd Support Level 13.61

See More

52-Week High 18.38
Last Price 15.40
Fibonacci 61.8% 14.51
Fibonacci 50% 13.31
Fibonacci 38.2% 12.11
52-Week Low 8.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar